1Zorat F, Shetty V, Dutt D, et al. The clinical and biological effects of thalidomide in patients with myelodysplastic syndromes. Br J Haematol,2001,115 :881-894.
2Deeg H J, Gotlib J, Beckham C, et al. Soluble TNF receptor fusion protein(TNF-α: Fc: Enbrel) in the treatment of patients with myelodysplastic syndrome(MDS). Blood, 2000,96 : 146a.
3Jonasova A, Neuwirtova R, Cermak J, et al. Cyclosporin A therapy in hypoplastie MDS patients and certain refractory anaemias without hypoplastie bone marrow. Br J Haematol, 1998,100 : 304- 309.
4Voulgari P V, Hatzimichael E C,Tsiara S,et al. Investigation for the presence of anti-erythropoietin antibodies in patients with myelodysplastic syndromes. Eur J Haematol, 2001,66 : 31 - 36.
5Yilmaz A, Kaufmann C C,Binder C,et al. Effects of amifostine in a patient with an advanced-stage myelodysplastic syndrome. Ann Hematol, 2001,80 :53- 57.
6Dai C H,Krantz S B,Kollar K,et al. Stem cell factor can overcome inhibition of highly purified human burstforming units-erythroid by interferon gamma. J Cell Physiol,1995,165: 323- 332.
7Catalano L, Selleri C, Califano C, et al. Prolonged response to cyclosporin-A in hypoplastic refractory anemia and correlation with in vitro studies. Haematologica,2000,85: 133- 138.
8Samuelsson J, Larfars G. Unusual clinical presentation in a patient with myelodysplastic syndrome, with subsequent hematological remission and suppression of the malignant clone following treatment with cyclosporine A, erythropoietin and granulocyte colony-stimulating factor. Leukemia Research, 1999,23 : 513- 517.
9Molldrem J J, Caples M, Mavroudis D, et al. Antithymocyte globulin for patients with myelodysplastic syndrome. Br J Haematol, 1997, 99 : 699- 705.
10Enright H,Jacob H S, Vercellotti G,et al. Paraneoplastic autoimmune phenomena in patients with myelodysplastic syndromes: response to immunosuppressive therapy. Br J Haematol, 1995,91:403-408.
